CD274 and non-small cell lung carcinoma: In this real-world evaluation of Stage IV NSCLC with PD-L1 ≥ 50% treated with single agent first-line pembrolizumab, we evaluate the rate of second-line therapy after pembrolizumab and predictive factors of second-line therapy in addition to evaluating patient outcomes.